Cutler Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Cutler Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,000	Closed	-$1K	–	5722
2017 Q4	$1K	Buy	+2,000	New	+$9.53K	﹤0.01%	4725

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's ECYT Position: Q2 2018 in Review

Cutler Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 900 shares — an estimated $8K sold.

Cutler Group first reported a position in ECYT in Q2 2016 and held it in 7 quarters. The position peaked at $57K in Q1 2017. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

Cutler Group reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Cutler Group sold 900 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $8K.
Cutler Group first reported a position in Endocyte, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
Cutler Group's Endocyte, Inc. Common Stock position peaked at $57K in Q1 2017.
114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.